Aragon Pharmaceuticals has announced the dosing of the first patient in its Phase I study of ARN-810 in estrogen receptor-positive breast cancer.
The Phase I dose escalation study, which will be conducted at Vanderbilt University, Mass General Hospital and Memorial Sloan-Kettering Cancer Center, will assess the safety and tolerability of ARN-810.
ARN-810 is an oral selective estrogen receptor degrader (SERD) designed to treat locally advanced or metastatic estrogen receptor-positive breast cancer in post-menopausal women.
The nonsteroidal agent degrades the receptor by binding to the estrogen receptor, inducing a conformational change.
Aragon Pharmaceuticals CEO Richard Heyman said ARN-810 is the most advanced candidate in its novel SERD programme.
"Today’s announcement represents a landmark step for us, as our SERD program originated within Aragon and is wholly-owned," Heyman said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
![](/wp-content/themes/goodlife-wp-B2B/assets/images/company-profile-unit.png)
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData"We are hopeful that ARN-810’s novel approach to breast cancer therapy will prove to be a more effective, sustained treatment option for this important patient population."
The Vanderbilt-Ingram Cancer Center clinical research associate director and breast cancer programme director Dr Carlos Arteaga said; "This drug may become another treatment option for many women with breast cancer."